177 related articles for article (PubMed ID: 19811111)
1. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of palivizumab in children with congenital heart disease in Germany.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):301-8. PubMed ID: 19811110
[TBL] [Abstract][Full Text] [Related]
3. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
[TBL] [Abstract][Full Text] [Related]
4. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
Committee on Infectious Diseases
Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
8. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of respiratory syncytial virus infections with palivizumab].
Ellingsen BB; Aase SA; Øymar K
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
[No Abstract] [Full Text] [Related]
10. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
12. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
Resch B; Müller W
Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus disease: update on treatment and prevention.
Krilov LR
Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
[TBL] [Abstract][Full Text] [Related]
14. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
Sunnegårdh J
Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
17. Health economics and RSV.
Carbonell-Estrany X; Lázaro y de Mercado P
Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
[TBL] [Abstract][Full Text] [Related]
18. Prevention of respiratory syncytial virus infection in high risk infants.
Prince AM; Jacobs RF
J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.
Harris KC; Anis AH; Crosby MC; Cender LM; Potts JE; Human DG
Can J Cardiol; 2011; 27(4):523.e11-5. PubMed ID: 21664100
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
